Adynovate in combination with Mypkfit offers personalized treatment and enables HCPs and patients to monitor factor levels from home and help achieve optimum QOL outcomes
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
Funds will be allocated to accelerate rapid production and high-end curation of whole genome sequences for its clinical application
Danish National Genome Center partners with Lifebit to deliver nationwide personalised medicine
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
A novel second-generation approach to achieve a safe, durable, and stable transgene expression to overcome the challenges of factor VIII replacement therapies
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Subscribe To Our Newsletter & Stay Updated
